Investigation of intravesical checkpoint-targeted therapy may warrant further investigation in patients with BCG-unresponsive bladder cancer.
Using intravesical checkpoint-targeted therapy was shown to be safe and resulted in clinical responses in a phase 1 trial (NCT02808143) that evaluated pembrolizumab (Keytruda) and BCG in patients who were unresponsive to BCG with non–muscle invasive bladder cancer (NMIBC). Joshua J. Meeks, MD, PhD, an associate professor at Northwestern University Feinberg School of Medicine, discussed the maximum tolerated dose (MTD) that resulted in dose-limiting toxicities (DLTs) during a poster presentation of the data at the 22nd Annual Meeting of the Society of Urologic Oncology.1
After a median follow-up of 33.4 months, the MTD was not reached, but 1 case of grade 2 diarrhea was reported, which lasted for 21 days, and required expansion of the second dose level. Investigators said the patient reached 52 weeks without recurrence.
The use of anti–PD-1 therapy is approved for the treatment of BCG-unresponsive NMIBC. Although intravesical administration of anti–PD-1 antibodies has not been tested, like systemic function it could provide similar or improved antitumor activity with less toxicity. However, to date no study has investigated the safety and efficacy of intravesical checkpoint immunotherapy.
The trial followed a 3 + 3 dose-escalation design which evaluated pembrolizumab at 1-, 2-, 5-, and 10-mg/kg. Nine patients received a single dose of pembrolizumab at week –2 for safety, and DLT was monitored during induction therapy when BCG was also administered between August 2017 and November 2019. Cohort 1 (n = 3) received pembrolizumab at 1 mg/kg and 50 mg BCG. Cohort 2 (n = 6) received 2 mg/kg and 50 mg BCG.
During the maintenance phase, beginning 2 weeks after the last dose of BCG, patients received pembrolizumab intravesically every 2 weeks for 12 weeks at weeks 7, 9, 11, 13, 15, and 17 for a total of 6 doses. Patients then received pembrolizumab intravesically every 4 weeks at weeks 21, 25, 29, 33, 37, 41, 45, and 49 for a total of 8 doses.
To be included in the trial, patients had to have a histologically documented recurrence of NMIBC, have persistent high-grade disease or be BCG refractory, have an ECOG performance status of 0 to 2, and have received 1 course of induction treatment with BCG.
The trial was stopped due to COVID-19.
Overall, 41 of 42 adverse events (AEs) were grade 1 to 3 and 15 were related to pembrolizumab (all grade 1). Six severe serious AEs occurred, with one at grade 5. All 9 patients recurred, with 6-month and 1-year recurrence-free rates of 66% and 33%. Progression occurred in 56% of patients, including 4 with extravesical disease (ie, 1 pelvis, 2 with upper tract urothelial cancer, 1 prostate). Three patients died, 2 from bladder cancer and 1 from myasthenia gravis. No serum levels of pembrolizumab were detected.
Intravesical pembrolizumab was well tolerated and, although not a primary objective, the investigators found reasonable rates of recurrence in this high-risk population. Despite intravesical delivery and no detection of systemic pembrolizumab, 1 patient had a grade 2 DLT and 1 had a grade 5 severe AE.
Investigation of intravesical checkpoint-targeted therapy may warrant further investigation in patients with BCG-unresponsive bladder cancer, the investigators wrote.
REFERENCE:
Meeks JJ, Cooley LF, Choy B, et al. Safety and efficacy of first-in-human phase I study of intravesical pembrolizumab and BCG in BCG-unresponsive non–muscle invasive bladder cancer. Poster presented at: 22nd Annual Meeting of the Society of Urologic Oncology; December 1-3, 2021; Orlando, FL. Accessed December 15, 2021. https://bit. ly/33lxzqz
Leon-Ferre Explores Targeting of PIK3CA Alterations in ER+ Breast Cancer
July 24th 2024During a live Community Case Forum event in partnership with the Minnesota Society of Clinical Oncology, Roberto A. Leon-Ferre, MD, discussed drugs targeting PIK3CA alterations in patients with ER+ metastatic breast cancer.
Read More
Roundtable Roundup: Treatment for Metastatic pMMR Endometrial Cancer
July 23rd 2024In separate, live virtual events, Michael J. Birrer, MD, PhD, and Jubilee Brown, MD, surveyed participants on the treatment of a postmenopausal woman with stage IVA endometrial cancer after first-line chemotherapy.
Read More
George Explores Impact of Risk Status With Cabozantinib/Nivolumab in Advanced RCC
July 19th 2024During a Case-Based Roundtable® event, Daniel George, MD, discussed the results of the CheckMate 9ER trial across favorable, intermediate, and poor risk groups in patients with advanced renal cell carcinoma.
Read More
Depth of Response With Quadruplet Regimens Considered in Newly Diagnosed Multiple Myeloma
July 18th 2024During a Case-Based Roundtable® event, Timothy Schmidt, MD, and participants discussed treatment selection for a 54-year-old patient with transplant eligible R-ISS stage 2/R2-ISS stage 3 IgG-κ myeloma.
Read More
Cretostimogene Grenadenorepvec Shows High CR Rate in BCG-Unresponsive NMIBC
July 17th 2024Mark D. Tyson, II, MD, MPH, discussed treatment with cretostimogene grenadenorepvec in high-risk Bacillus Calmette-Guérin-unresponsive non-muscle invasive bladder cancer with carcinoma in situ and data from the BOND-003 trial.
Read More
Rossetti Reviews Myelofibrosis Risk Stratification and Outcome Data for Pacritinib
July 17th 2024During a Case-Based Roundtable® event, James M. Rossetti, DO, discussed the role of risk scoring and stratification tools and treatment for a patient with declining hemoglobin and platelet counts due to primary myelofibrosis.
Read More